Fund of the week: Delos Capital
Delos Capital is a life sciences venture capital firm headquartered in Hong Kong, with operating presence in Cambridge, Massachusetts, and Shanghai. It invests in therapeutics and medical technology companies across the United States and Greater China.
The firm combines conventional venture investing with active company creation through its in-house incubator, Delos Foundry. It was founded in 2014 by Henry Chen, a former Partner and Co-Head of Asia at Permira who previously spent nine years at Goldman Sachs as Managing Director and co-head of the General Industrials Group for Asia ex-Japan.
Delos sits in a structurally different position from the philanthropic and royalty vehicles previously covered in this series. It is a closed-end limited partnership, raises capital from institutional limited partners and family offices on a fund-by-fund basis, and writes equity checks across seed, Series A, and growth rounds in privately held companies.
As of its most recent disclosed close, the firm has raised three funds, with Fund III holding its first close at $300 million in February 2022 after six months of fundraising. All Fund II investors re-upped or upsized into the new vehicle.
For a royalty investor, biotech BD executive, or technology transfer office, Delos is interesting for a specific reason. Several portfolio companies have generated material out-licensing transactions to large pharma with disclosed royalty obligations.
The most prominent are the AstraZeneca licence of Eccogene's ECC5004, the Eli Lilly collaboration with TRexBio, and the CRISPR Therapeutics co-development with Sirius Therapeutics.
Each one sits on a Western pharma counterparty's balance sheet and represents a candidate for milestone monetisation or synthetic royalty structuring downstream.
This piece looks at who Delos is, who funds it, what its portfolio looks like, what its disclosed royalty stacks look like, and how a balanced reading should weigh the strengths of the model against the risks specific to its cross-border, company-creation approach.
Overview and investment focus
Delos Capital invests across therapeutics and medical technology in immunology, oncology, cardiometabolic disease, neurology, infectious disease, rare disease, and interventional medtech.
The portfolio page lists more than thirty active and exited companies spanning three funds, with assets ranging from early preclinical incubations to NASDAQ-listed companies.
The investment thesis rests on three structural propositions.
First, that the most productive life sciences capital allocation today connects North American discovery science with Greater China development and operational capacity. The firm describes itself as investing in growth platforms in Greater China and relevant innovation in the United States, and as creating value through cross-portfolio collaboration.
Second, that a meaningful share of the most attractive opportunities in life sciences are not available to fund through conventional Series A or B participation, because the companies do not yet exist. The Delos Foundry programme is the operational answer to that constraint: an in-house incubator that originates therapeutic concepts, builds NewCos around them, and finances them to clinical proof of concept.
Third, that biotech investing benefits from deep scientific and operating networks in both ecosystems. The firm assembles these through its venture partners, senior advisors, and founding partner Samuel Yin, President and CEO of Ruentex Group and an established figure in Taiwanese industrial and financial services.
The result is a portfolio with three distinct exposure profiles.
Traditional venture positions in US-headquartered biotech and medtech include Imperative Care, Avenzo Therapeutics, Alpha-9 Oncology, TRexBio, Ensoma, and Averna Therapeutics.
Cross-border companies operating across both regions include Eccogene, Sirius Therapeutics, Clover Biopharmaceuticals, and Phanes Therapeutics.
Foundry-originated incubations are the third category. The May 2026 collaboration with AP Biosciences on bispecific and trispecific antibodies in autoimmune disease is the most recent disclosed example.
Background and formation
Henry Chen founded Delos in 2014 after spending six years at Permira as a partner and co-head of the firm's Asia practice. He had previously been a Managing Director at Goldman Sachs covering consumer retail, healthcare, industrials, and transportation across Asia ex-Japan, and a corporate finance lawyer at Davis Polk in New York and Hong Kong.
His operating experience, including periods as CEO and Chairman of Tanvex BioPharma, shaped the firm's bias toward active, hands-on involvement with portfolio companies rather than passive minority positions.
Samuel Yin came in as a founding partner. His involvement gave Delos an unusual capital base for a first-time fund.
Rather than relying solely on conventional institutional fund-of-funds and endowments, the firm could anchor on Yin's network and on capital pools associated with Ruentex Group. Ruentex is a Taiwanese industrial conglomerate with major holdings in Nan Shan Insurance and Sun Art Retail Group, the operator of RTMart and Auchan hypermarkets in China.
Yin is also the founder of the Tang Prize, established in 2012 to recognise research benefiting humanity.
Fund I was followed by Fund II and Fund III, with the third vehicle reaching a $300 million first close in just six months in early 2022.
The firm has not publicly disclosed the final close size of Fund III, the precise composition of its limited partner base, or the proportion of capital coming from Greater China versus US investors.
Its own statements describe Fund III's investor base as drawing from reputable investors across the US and Greater China, with full Fund II investor re-up.
Limited partners and funder base
This is the section where direct, verifiable information is thinnest, and where this profile relies more heavily on inference than on disclosure.
Delos Capital does not publish its LP base. Unlike public pension funds with US allocations or large sovereign wealth investors with public commitment disclosures, the firm has not been the subject of detailed LP reporting in the trade press.
What is reasonably inferable, based on public sources and the firm's own statements:
| Likely or known LP category | Basis |
|---|---|
| Founding partner capital (Samuel Yin / Ruentex-aligned vehicles) | Founding partner role; documented Taiwanese industrial base |
| US institutional investors (endowments, fund of funds, family offices) | Firm's public statement of "US and Greater China" LPs in Fund III first close |
| Greater China institutional and family office capital | Same statement; Hong Kong domicile; Greater China operating presence |
| Senior advisor and venture partner co-investment | Standard structure; documented Senior Advisors include H.T. Kung (Harvard), Counde Ouyang, and Yuji Kato |
| Strategic corporate LPs in Asian pharma or industrial conglomerates | Inferred from the firm's cross-border deal flow and venture partner network; not publicly disclosed |
Identifiable LP names are not in the public record, and any specific attribution beyond the founding partner relationship would be speculation.
A reader who needs verified LP information should consult PitchBook's Fund III profile or commission a specific intelligence request. Form ADV and Form PF filings would not capture a Hong Kong-domiciled fund.
It is worth noting that this opacity is normal for Hong Kong-domiciled venture funds, not specific to Delos. Compared to an SEC-registered US venture fund, a Hong Kong-headquartered vehicle has materially fewer LP transparency obligations, and Delos's public communications do not appear to deviate from market practice in that regard.
Portfolio of investments
The public portfolio is organised by fund (I, II, III), therapeutic area (cardiometabolic, immunology, infectious disease, neurology, oncology, rare disease, other), and product type (therapeutic, medtech). The list spans more than thirty companies.
Selected positions of particular relevance to the royalty and BD audience:
| Company | Stage / status | Notes |
|---|---|---|
| Eccogene | Clinical / cross-border | Out-licensed ECC5004 to AstraZeneca for $185M upfront, $1.825B in milestones, tiered royalties on net sales; filed for Hong Kong IPO in late 2025 at ~$498M valuation |
| TRexBio | Private, clinical | $55M upfront from Lilly plus >$1.1B milestones and tiered royalties on three programs; $84M Series B in November 2024; $50M Series B extension in January 2026 |
| Sirius Therapeutics | Private, clinical | $95M upfront from CRISPR Therapeutics ($25M cash + $70M equity), >$800M milestones, tiered royalties high single to low double digits on additional siRNA programs, 50/50 cost-and-profit on SRSD107 |
| Zenas BioPharma | Public (NASDAQ: ZBIO) | Priced upsized IPO in September 2024; clinical-stage immunology |
| Syndax Pharmaceuticals | Public (NASDAQ: SNDX) | Cancer therapeutics; earlier public exposure |
| Clover Biopharmaceuticals | Public (HKEX: 2197) | I/O and vaccine platforms |
| Tanvex BioPharma | Public (TWSE: 6541) | Biologic CDMO and biosimilar developer; Henry Chen served as CEO and Chairman |
| Alpha-9 Oncology | Private, clinical | Targeted radiopharmaceuticals; closed a $175M Series C |
| Avenzo Therapeutics | Private, clinical | Closed $60M Series B in September 2025; CDK2 selective inhibitor |
| Imperative Care | Private, commercial | Interventional stroke; acquired Truvic in 2021 |
| Eccogene, Sirius, Phanes | Cross-border | US discovery and Greater China development |
According to public secondary sources, Delos has exited approximately five companies via IPO and three via acquisition across its three funds.
Royalty stack analysis
This section is the one most readers of p05.org will want first. Three Delos portfolio companies have generated disclosed out-licensing transactions to Western pharma counterparties with explicit royalty obligations, and each has a sufficiently distinctive deal structure to warrant separate treatment.
Eccogene / AstraZeneca (ECC5004, oral GLP-1RA)
Counterparty. AstraZeneca, with global rights ex-China and shared rights in China.
Headline economics. $185 million upfront on signing in November 2023, plus up to $1.825 billion in clinical, regulatory, and commercial milestones, plus tiered royalties on net product sales.
Royalty rate. Not publicly disclosed in the original press release. The Hong Kong IPO prospectus filed in October 2025 is the place to look for tier breakdowns, though the most-cited secondary sources do not republish them.
Stack structure. Single-tier outbound royalty, with no disclosed academic or upstream in-licence obligation above it.
ECC5004 was internally invented at Eccogene by founders Jingye Zhou and Jianfeng Xu, both ex-Lilly chemistry. The chemistry was developed inside Eccogene rather than in-licensed from Lilly or an academic source.
There is no second-tier obligation visible to the royalty buyer above what AstraZeneca pays to Eccogene.
Competitive context. ECC5004 is in Phase 2 development against Eli Lilly's orforglipron and Novo Nordisk's oral semaglutide, both well ahead in the oral GLP-1 race.
AstraZeneca added the $4.7 billion CSPC deal in January 2026, which expanded its obesity pipeline but also reduced ECC5004's relative weight inside AZ's portfolio.
Royalty buyer view. An attractive but heavily competitive Phase 2 asset with a single-tier outbound.
If ECC5004 reaches commercialisation, the royalty would be material. The probability-weighted value depends almost entirely on how the asset positions relative to orforglipron data over the next 18-24 months.
TRexBio / Eli Lilly (Deep Biology Platform, three programs)
Counterparty. Eli Lilly and Company, with exclusive worldwide rights.
Headline economics. $55 million upfront in January 2023, more than $1.1 billion in development, regulatory, and commercial milestones across three programs, plus tiered royalties on product sales.
Royalty rate. Not publicly disclosed.
Stack structure. Three-program licence with a single counterparty. Royalty obligations attach to each program separately.
TRB-051, the first program to enter the clinic, began Phase 1 in June 2024 and triggered a double-digit million dollar milestone payment to TRexBio.
TRexBio has also disclosed a separate Johnson & Johnson option exercise on a different anti-inflammatory program, although J&J terms have not been published in detail.
Stack diagram. Lilly → royalty → TRexBio, with TRexBio retaining wholly owned TRB-061, TRB-071, and TRB-081 programs in parallel.
There is no disclosed academic in-licence above TRexBio for the partnered programs. The Deep Biology platform appears to be internally developed.
Royalty buyer view. A platform deal in immunology with three swings, each in early clinical or preclinical.
The platform partner (Lilly) is one of the most credible counterparties for autoimmune commercialisation. The royalty stream is high probability-weighted on at least one program reaching the market over the contract life, with the milestone curve front-loaded to Phase 2 and Phase 3 readouts.
Sirius Therapeutics / CRISPR Therapeutics (SRSD107 and platform options)
Counterparty. CRISPR Therapeutics, with US lead commercialisation rights and Sirius leading in Greater China.
Headline economics. Announced May 2025. Upfront of $95 million ($25M cash + $70M equity investment in Sirius), plus up to $800 million in milestone payments across the collaboration.
Royalty rate. This is the most informative disclosure across the Delos portfolio.
On the additional siRNA programs that CRISPR has the option to license, Sirius is eligible to receive tiered royalties ranging from high single to low double digits.
On SRSD107 itself, the structure is different: 50/50 cost-and-profit split, not a conventional royalty.
Stack structure. This is the most stack-interesting of the three deals.
For SRSD107 (Factor XI siRNA for thromboembolic disorders):
| Layer | Holder | Mechanism |
|---|---|---|
| US commercial profit | CRISPR Therapeutics (lead) / Sirius (50% share) | 50/50 profit and cost split |
| Greater China commercial profit | Sirius (lead) / CRISPR (50% share) | 50/50 profit and cost split |
| Equity in Sirius | CRISPR | $70M equity investment received as part of upfront |
For the optional additional siRNA programs:
| Layer | Holder | Mechanism |
|---|---|---|
| Outbound royalty | Sirius (recipient) | Tiered, high single to low double digits, on net sales |
| Milestone payments | Sirius (recipient) | Development, regulatory, commercial |
| Research funding | CRISPR (payer) | Funds research for each optional target |
Royalty buyer view. SRSD107 is the most interesting asset. It is in Phase 2 in Europe and China, with a differentiated long-acting profile (twice-yearly dosing) against Bayer's asundexian and Bristol Myers Squibb's milvexian.
The 50/50 profit-share structure is not a conventional royalty and would require synthetic structuring to monetise.
The optional additional siRNA programs, with their disclosed high-single-to-low-double-digit tiered royalty, are more conventionally bankable, but they are not yet specified by target.
A royalty buyer underwriting Sirius would underwrite the platform optionality more than SRSD107.
Summary of Delos-relevant royalty obligations
| Portfolio company | Counterparty | Upfront | Milestones | Royalty | Status |
|---|---|---|---|---|---|
| Eccogene | AstraZeneca | $185M | up to $1.825B | Tiered, not disclosed | Phase 2 |
| TRexBio | Eli Lilly | $55M | >$1.1B (3 programs) | Tiered, not disclosed | Phase 1 (TRB-051) |
| TRexBio | Johnson & Johnson | undisclosed | undisclosed | undisclosed | Option exercised |
| Sirius Therapeutics | CRISPR Therapeutics | $95M ($25M+$70M equity) | >$800M | High-single to low-double digits on platform options; 50/50 profit-share on SRSD107 | Phase 2 (SRSD107) |
For a royalty fund mapping Delos's portfolio against its own pipeline, three points matter.
The underlying assets are spread across three different downstream counterparties (AZ, Lilly, CRISPR). The rate disclosures are partial in two cases and explicit in the third. And the most interesting near-term asset (SRSD107) is not a conventional royalty but a profit-share that requires structural creativity to underwrite.
Leadership
| Person | Role | Background |
|---|---|---|
| Henry Chen | Founder, Managing Partner | Permira (Partner, Co-Head Asia); Goldman Sachs (Managing Director); Davis Polk; Harvard undergraduate, Harvard Law; co-founder of Curamir Therapeutics and Tulavi Therapeutics; former CEO and Chairman of Tanvex BioPharma |
| Eric Huang, Ph.D. | Partner | Investment lead |
| Tej Pavoor, Ph.D. | Partner | Investment lead |
| Tim Xiao | Partner | Investment lead |
| Lee Cooper | Managing Director | Investment lead |
| Yang Cheng, Ph.D. | Associate | Investment professional |
| Samuel Yin, Ph.D. | Founding Partner | President and CEO of Ruentex Group; founder of the Tang Prize |
| Frank Chen | Partner | Senior team |
| Michael Su, Ph.D., Counde Ouyang, Ph.D., H.T. Kung, Ph.D., Yuji Kato | Senior Advisors | Scientific and operating networks across the US, Taiwan, and Japan |
The team also lists a separate operations team and remembers Dr. Michael Chang in memoriam.
Blue Team: the case for Delos Capital
The blue team writes the bull case as a competent advocate would: not as marketing copy, but as the strongest defensible argument an LP advisor or BD counterpart could put on paper.
A genuine cross-border edge, validated by multiple deals. The Eccogene-AstraZeneca licence is not a one-off. The TRexBio-Lilly platform deal and the Sirius-CRISPR collaboration represent two further validation points, both in 2023-2025, with three different Western pharma counterparties.
The combined upfront payments received by Delos portfolio companies across these three deals are $335 million in cash plus $70 million in CRISPR equity, with potential milestones aggregating well above $3 billion.
For a royalty-attentive reader, that is not a thesis story. It is realised deal flow.
Company-building capacity as a structural differentiator. Many specialist biotech funds claim incubation capability and few execute it well. The Delos Foundry is unusual in that it is presented as a core part of the firm's identity rather than a sidecar activity.
The May 2026 collaboration with AP Biosciences is a templated example. Delos leads therapeutic ideation, financing, and strategic development. APBio contributes its Omni-Mab and T-Cube bispecific antibody platforms. For a biotech BD executive, this is a different counterparty than a passive minority investor.
LP confidence in the form of full re-ups. The disclosure that all Fund II investors re-upped or upsized into Fund III, with the first close completed in six months, is not a vanity statement.
In a venture environment that has tightened materially since 2021, that kind of LP retention is meaningful. It implies that Fund I and Fund II performance is at least adequate to retain a base of sophisticated LPs and probably above the median for vintage peers.
Operating depth at the top of the firm. Henry Chen's profile, including Goldman Sachs, Permira, Davis Polk, and operating roles at Tanvex and as co-founder of multiple portfolio companies, is unusual for a specialist life sciences VC of this size.
Most venture firms of comparable AUM lead with a science-trained or BD-trained partner. Delos has a generalist private equity and capital markets professional as its operating CEO, with science-trained partners and advisors providing therapeutic depth. For a Western LP, this is a recognisable Goldman-Permira pedigree wrapped around a specialist mandate.
Royalty-relevant pipeline. Several portfolio companies sit in therapeutic areas where royalty buyers are most active.
Oncology (Syndax, Avenzo, Alpha-9), immunology (Zenas, TRexBio, AP Biosciences via the Foundry collaboration), and cardiometabolic disease (Eccogene, Sirius) are the three areas where royalty fund deal flow has been most concentrated over the past three vintages.
A royalty fund that tracks Delos's portfolio is effectively monitoring a leading indicator of out-licensing supply.
Red Team: the case against Delos Capital
The red team writes the bear case with equal rigour. The point of a red team is not to be unfair to the firm but to surface every concern that an LP advisor, royalty buyer, or BD counterpart would want answered before committing capital, signing a licence, or buying a milestone stream.
Cross-border China exposure is a structural headwind, not a tailwind. The single biggest external change since Delos Fund III's first close in February 2022 has been the deterioration of the US-China life sciences operating environment.
The Biosecure Act discussions, evolving CFIUS scrutiny of biotech transactions with PRC links, NIH grant restrictions on certain Chinese collaborations, and growing US pharma caution on Chinese-origin clinical data all constrain the exact cross-border value proposition that Delos's thesis depends on.
The firm's public language about Greater China and US synergies reads differently in 2026 than it did in 2022.
Whether this is a fund-killer, a manageable headwind, or an outright tailwind (because differentiated cross-border capability becomes more scarce and therefore more valuable) is a real strategic question. Neither Delos's public communications nor secondary press coverage gives a clear answer.
The Eccogene exit is not yet an exit. The AstraZeneca licence is a meaningful endorsement of Eccogene's chemistry, but it is not a realisation event for Delos's equity position.
Eccogene filed for a Hong Kong IPO in late 2025 at a valuation that, on the trajectory disclosed in its prospectus, would imply roughly a 17x mark from its Series A. That paper mark is meaningful but is not cash distributed to LPs.
Hong Kong biotech listings have a mixed post-IPO record, and the ECC5004 programme is competing against Lilly's orforglipron, Novo's oral semaglutide, Pfizer, and Structure Therapeutics.
A royalty buyer looking at the AstraZeneca milestone stream as a synthetic royalty target would need to underwrite a candidate that is well behind in the class.
Royalty rate disclosure is partial. Across the three major royalty-bearing licences (Eccogene/AZ, TRexBio/Lilly, Sirius/CRISPR), only Sirius has disclosed a specific royalty range (high single to low double digits) and only on the optional additional siRNA programs.
The Eccogene and TRexBio rate tiers are not in the public record, which means any royalty buyer modelling these obligations must rely on private intelligence or comparable-deal benchmarks for the rate.
SRSD107 itself, the most interesting Sirius asset, is structured as a 50/50 profit share rather than a conventional royalty, which makes it harder to monetise through standard royalty structures.
Limited LP transparency. This is not a criticism of the firm so much as a flag for any reader who would weigh Delos against a peer with US-style disclosure.
The LP base is not public, the headline numbers for Fund I and Fund II final closes are not in the public record, and there is no published DPI, RVPI, or net IRR for any Delos vintage. A US-allocator-with-fiduciary-duty reader will treat the firm's track record as opaque until it sees its own data room.
Concentration of decision authority on one operating principal. Delos's public profile is materially shaped by Henry Chen, with Samuel Yin as a founding partner whose primary role is at Ruentex and the Tang Prize rather than day-to-day investment execution.
The investment team includes named partners, but the firm does not present a deep public bench of senior decision-makers in the way that OrbiMed or Foresite Capital does. Key person risk is a real input into LP underwriting.
Foundry economics are unproven at this stage. Incubation models look efficient on paper and are often more expensive in practice than they appear, because the firm absorbs operating overhead during the NewCo's pre-Series-A phase.
The AP Biosciences collaboration is interesting but is too new to evaluate as an exit-generating engine. A red-team underwriter would note that the announcement is dated May 11, 2026, and that not one Foundry-originated company has yet produced a disclosed exit at the time of writing. Investors who weigh actual realised performance over thesis-quality should treat the Foundry as an option, not a proven model.
No royalty exposure for the fund itself. Delos does not run a royalty book, does not hold revenue interests, and does not provide synthetic royalty or structured credit to portfolio companies.
Its returns are entirely conventional equity venture returns, which means a royalty-fund or structured-credit reader is looking at Delos as a source of deal flow rather than as a peer in the royalty market.
That is a different relationship than Delos has with traditional biotech VC LPs and is worth flagging clearly.
Implications for the pharmaceutical royalty and biotech capital markets
For a royalty fund, Delos is interesting primarily as an originator of assets that subsequently generate royalty streams in the hands of large pharma counterparties.
The three concrete examples are Eccogene-AstraZeneca, TRexBio-Lilly, and Sirius-CRISPR. The milestone and royalty obligations sit on AstraZeneca, Lilly, and CRISPR respectively, and each represents a candidate target for a synthetic royalty or milestone monetisation depending on the structuring preferences of the originator.
Avenzo, Alpha-9 Oncology, and the Foundry-originated NewCos sit at stages where partnered out-licensing is plausible over the next two to four years, with the same downstream implications.
For a biotech BD executive at large pharma, Delos is most relevant as a counterparty in cross-border in-licensing. The firm's combination of US-headquartered NewCos and Greater China operational capacity is exactly the structural setup that has produced an outsized share of recent oral small molecule, siRNA, and bispecific antibody licensing transactions to Western pharma.
A BD team that is not already tracking Delos's portfolio is missing one of the more productive deal-flow sources in that segment of the market.
For a technology transfer office, Delos is a relevant secondary buyer of academic IP, particularly through the Foundry channel. The firm's stated approach of building NewCos around well-defined clinical needs is consistent with the kind of TTO out-licensing arrangement where the academic institution retains royalty interests in a Delos-founded NewCo.
Recent developments (2024 to May 2026)
| Date | Event |
|---|---|
| June 2024 | Lilly initiates Phase 1 of TRB-051, triggering double-digit million milestone payment to TRexBio |
| September 2024 | Zenas BioPharma prices upsized IPO on NASDAQ (ZBIO) |
| November 2024 | TRexBio closes $84M Series B; J&J exercises option on separate program |
| May 2025 | Sirius Therapeutics and CRISPR Therapeutics announce strategic collaboration on SRSD107 and additional siRNA programs |
| September 2025 | Avenzo Therapeutics closes $60M Series B; first patient dosed in SRSD107 Phase 2 |
| October 2025 | Eccogene files for Hong Kong IPO at ~$498M valuation |
| January 7, 2026 | STRM.BIO Series Seed 2 financing with Recordati and Boehringer Ingelheim Venture Fund |
| January 27, 2026 | TRexBio closes oversubscribed $50M Series B extension with Janus Henderson, Balyasny, Affinity Asset Advisors joining the syndicate |
| May 11, 2026 | Delos Capital and AP Biosciences announce venture creation collaboration on bispecific and trispecific antibodies in autoimmune disease |
Conclusion
Delos Capital is a fund that resists easy classification. It is a Hong Kong-headquartered cross-border life sciences VC with a US operating presence, a Goldman-Permira-pedigreed managing partner, a Taiwanese industrial founding partner, and a company-building incubator that is becoming a larger share of its identity.
The royalty-relevant case for the firm is now stronger than it was 18 months ago.
Three portfolio companies (Eccogene, TRexBio, Sirius) have generated material out-licensing transactions to AstraZeneca, Lilly, and CRISPR Therapeutics respectively. The combined disclosed upfronts are $335 million plus $70 million in equity, milestone obligations exceed $3.7 billion, and there are three separate royalty streams.
That is a meaningful population of underlying assets for the royalty market to monitor.
Its single largest structural risk, the deterioration of the US-China life sciences operating environment, has moved against the firm's thesis since Fund III began deployment.
A blue team reading the firm sees a differentiated cross-border platform with documented LP re-up, a credible operating principal, and a portfolio that is starting to produce both public-market and licensing realisations.
A red team reading the same firm sees opaque LP transparency, an unrealised Eccogene mark, a Foundry model that is too new to underwrite, partial royalty rate disclosure across the three major outbound licences, and a geopolitical headwind that the firm's own public language has not yet directly addressed.
Both readings are defensible from the public record, and a careful LP, royalty buyer, or BD counterpart would want to understand which reading the next two vintages of portfolio activity will tend to confirm.
For commercial capital markets, the immediate practical question is narrower. Delos is one of a small number of specialist venture firms whose portfolio is producing out-licensing transactions to large pharma at a rate that matters for royalty fund deal flow.
That alone is reason to keep the firm in the field of view, regardless of where one comes out on the broader thesis.
All information in this article was accurate as of May 2026 and is derived from publicly available sources including Delos Capital's own website and press releases, regulatory and trade publications, and financial news reporting. Information may have changed since publication. This content is for informational purposes only and does not constitute investment, legal, or financial advice. The author is not a lawyer or financial adviser.